Two Sessions Time | National People's Congress Representative, Lu Qingguo from Chenguang Biotech Group: Improve the quality standards of Chinese Patent Medicine, regulate the centralized procurement model for Traditional Chinese Medicine, and optimize the

① Lu Qingguo, Director of Chenguang Biotech Group and a representative of the National People's Congress, focused on several recommendations at this year's Two Sessions, including optimizing the procurement mechanism for Traditional Chinese Medicine, enhancing the quality standards for Chinese Patent Medicine, and standardizing the Traditional Chinese Medicine granule industry; ② In addition to recommendations related to the Traditional Chinese Medicine industry, Lu Qingguo prepared several suggestions on rural social retirement insurance, rural medical insurance, and increasing support for companies sanctioned by the United States.

cls.cnMar 3 10:09

Guizhou Yibai Pharmaceutical Leads Our Trio Of Promising Penny Stocks

Yahoo FinanceFeb 6 11:06

Guizhou Yibai Pharmaceutical Co., Ltd. 2024 Annual Results Forecast

SZSIJan 18 00:00 · Announcements

Guizhou Yibai Pharmaceutical (600594.SH): Expected loss of 0.285 billion yuan to 0.342 billion yuan in 2024.

Gelonghui reported on January 17 that Guizhou Yibai Pharmaceutical (600594.SH) announced its annual performance forecast for 2024, expecting a net income attributable to the parent company's owners to be between -342 million yuan and -285 million yuan; this represents a loss compared to the same period last year. The company expects a net income attributable to the parent company's owners, excluding non-recurring gains and losses, to be between -348 million yuan and -290 million yuan for 2024.

Gelonghui FinanceJan 17 16:59

Guizhou Yibai Pharmaceutical (600594.SH): has actually repurchased 0.95% of the company's shares.

On November 28, Guizhou Yibai Pharmaceutical (600594.SH) announced that the repurchase period for company's shares has expired on November 28, 2024. The company has completed the share repurchase, having actually repurchased 7,533,500 shares through centralized bidding trading method, accounting for 0.95% of the total share capital. The highest price for the repurchase was 4.10 yuan/share, the lowest price was 2.89 yuan/share, the average repurchase price was 3.32 yuan/share, and the total amount paid was 24,991,703 yuan (excluding trading commissions and other transaction fees).

Gelonghui FinanceNov 28, 2024 18:56

Guizhou Yibai Pharmaceutical (600594.SH): Currently, the company's major health products focus on throat lozenges, instant drinks, solid beverages, etc.

Gelonghui November 11th | Guizhou Yibai Pharmaceutical (600594.SH) stated on the investor interaction platform that the company's current anti-tumor products include injection of oxaliplatin, Kansai Di capsules, and Aiyu capsules. Currently, the company's large health products are mainly focused on throat lozenges, instant drinks, solid beverages, etc.

Gelonghui FinanceNov 11, 2024 18:00